| アブストラクト | Background: Nearly 10 billion doses of the various messenger ribonucleic acid (mRNA) and viral vector vaccines against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) have been administered worldwide. Adverse drug reactions (ADRs) have been overwhelmingly mild to moderate in nature. Rare side effects have included myocarditis/pericarditis, thrombosis with thrombocytopenia syndrome (TTS), Guillain-Barre Syndrome (GBS), and death. However, vaccine-related ADR data are still being collected using a variety of reporting systems. Purpose: We will describe a case of suspected mRNA coronavirus disease 2019 (COVID-19) booster-related rhabdomyolysis in a woman who developed signs and symptoms 10 days after administration of the vaccine dose. With a Naranjo ADR probability score of 4, the vaccine was deemed to be a possible cause of our patient's rhabdomyolysis. Methods: A search of the VAERS (Vaccine Adverse Event Reporting System) mined in November 2021 revealed 386 reported cases of COVID-19 vaccine-related rhabdomyolysis. However, system limitations make the utility of the information problematic. Conclusions: It is vitally important that clinicians, scientists, and patients are aware of rhabdomyolysis as a potential side effect of vaccination. Suspected vaccine-related ADRs should be promptly and accurately reported via VAERS or other surveillance systems to support the ongoing effort to ensure vaccine safety. |
|---|
| ジャーナル名 | The Journal of pharmacy technology : jPT : official publication of the Association of Pharmacy Technicians |
|---|
| 投稿日 | 2022/7/15 |
|---|
| 投稿者 | Unger, Kendra; Ponte, Charles D; Anderson, Dylan |
|---|
| 組織名 | Department of Family Medicine, West Virginia University School of Medicine,;Morgantown, WV, USA.;Department of Clinical Pharmacy, School of Pharmacy, West Virginia University,;West Virginia University School of Medicine, Morgantown, WV, USA. |
|---|
| Pubmed リンク | https://www.ncbi.nlm.nih.gov/pubmed/35832563/ |
|---|
